PITTSBURGH - The doctor had barely pulled away the needle when a blister appeared on Tracey Berg-Fulton's abdomen: An experimental shot was revving up the 24-year-old's immune system - part of a bold quest to create a vaccine-like therapy for diabetes.
"If we're right, that is what's going to stop Type 1 diabetes," said Dr. David Finegold as he watched the blisters appear - one to match each of four shots - with intense satisfaction.
It's a big "if." The research is in its infancy, a first-step experiment to be sure the vaccine approach is safe before researchers at Children's Hospital of Pittsburgh test their real target - kids newly diagnosed with this deadliest form of diabetes.
It's also part of a big shift: Scientists increasingly hope to control Type 1 diabetes by curbing the rogue immune cells that cause it, before patients become completely dependent on daily insulin injections to survive.
"Treating at onset in children is the best chance we have," said Pittsburgh immunologist Dr. Massimo Trucco, whose novel vaccine - made from patients' own blood - is among a handful of possible immune therapies being tested around the country.
About 3 million Americans have Type 1 diabetes, where the body mistakenly attacks and destroys cells in the pancreas that produce insulin, the hormone crucial to converting blood sugar to energy. It's different from the far more common Type 2 diabetes that is usually linked to obesity, where the body produces insulin but gradually loses the ability to use it properly. Type 2 patients have more treatment options, including diet and exercise.
To stay alive, Type 1 patients must rigorously inject insulin, or wear a pump that infuses it.
' "Type 2 gets all the attention. This is Type 1 - we die from this," said Berg-Fulton of Millvale, Pa., who was diagnosed just before her 10th birthday.
Hence the new push for immune therapy. Preserve enough precious insulin-producing cells before irreversible damage is done and maybe patients would need far less insulin, perhaps only occasional injections like when they splurge on ice cream.
But how? A "therapeutic vaccine" must shut down T cells that are the immune system's attack dogs, racing out to tackle infections or other invaders - but only the faulty ones that erroneously attack a Type 1 diabetic's own pancreas. Body-wide immune suppression would leave patients vulnerable to other illnesses.
Rather than a drug, Trucco's government-funded strategy: He blocks the 911 call that different white blood cells send to direct T cells to the pancreas. They're called dendritic cells, and altering three communication molecules on their surface basically confuses and paralyzes the T cells. In mice and monkeys, the reprogrammed cells ended the vicious cycle of a pancreas attack that in turn attracts more T cells to attack again.
Exploring all the different immune-altering methods is important because combinations may be needed, said Dr. Richard Insel of the Juvenile Diabetes Research Foundation. Maybe a quick hit on T cells like antibodies might offer, followed by some gentler cell-based vaccines to keep them in check. But "these are early days," he cautioned.
Back in April, Berg-Fulton donated her own blood so researchers could filter out immature dendritic cells and reprogram them. Reinject them just inside the skin over the pancreas - no deeper than a pinprick - and Trucco's animal experiments show the cells somehow find their way back to that organ to start working.
For now, Berg-Fulton is part of a safety test, one of 15 adult diabetics being injected to make sure there are no unexpected side effects before researchers test if reprogrammed cells might really protect children's pancreas cells. Even if the vaccine ultimately works, she's had diabetes too long to benefit, Finegold carefully explained when she volunteered.
"I'd be lying to say I'm not a little disappointed" at that, Berg-Fulton told him. Think long-term, Finegold responded. If doctors one day learn to restore insulin production, they'll need to keep the faulty immune system from just destroying it again.
Comments
Use the comment form below to begin a discussion about this content.
Sign in to comment